Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The aim of this study is to evaluate the potential benefits in implantation, clinical pregnancy and live birth rates by an endometrial biopsy prior to an IVF/ICSI treatment. Including a follow up on possible pregnancy complications and data on children at birth.

Further it is planned to aspirate secretions from the uterus and take blood samples during the treatment, which presumably can provide information about the mechanisms underlying the possible effect of the treatment.


Options:
A: Inclusion Criteria:

* Patients are undergone intrauterine insemination with gonadotropin stimulation
* Bilateral patent fallopian tubes revealed by hysterosalpingography or laparoscopy
* After semen preparation for intrauterine insemination, total progressive sperm count \> 5 million

Exclusion Criteria:

* endocrin or metabolic disorders,
* uterine factor,
* pelvic inflammatory disease,
* women with basal follicle-stimulating hormone (FSH) level \>15 IU/mL,
* body mass index (BMI) ≥ 35 kg/m2,
* age ≥ 40 and \< 18 years,
B: Inclusion Criteria:

* One or more previous failed implantation despite transfer of good quality embryons/blastocyst in a fresh IVF/ICSI treatment
* Planned Antagonist treatment
* Planned Standardized hormone treatment
* FSH: 2-12 IU/L
* Age: 18-40 years
* BMI: 18-32
* Regular menstrual cycles
* Written consent

Exclusion Criteria:

* Patients in need for a interpreter
* Suspected intrauterine abnormalities ( fibromes, polyps, adenomyosis, sactosalpinges)
* Planned use og Assisted hatching or use of specialized media
* Previous inclusion in the study
C: Inclusion Criteria:

Women undergoing first or second IVF cycle, with or without ICSI

* Age 18-39
* BMI 18-35 kg/m2
* Uterine cavity evaluation (hysterosalpingogram, sonohysterogram, hysteroscopy) in the preceding 24 months
* Early follicular phase (Day 2 or Day 3) serum FSH, evaluated in the preceding 6 months

ONE of the following:

* Non- oral contraceptive pill (non-OCP) subjects: Documented LH surge 9-11 days prior to enrollment
* Current OCP subjects: OCP use for ≥ 10 days
* Use of long GnRH agonist or GnRH antagonist protocol
* Subject able to give informed consent

Exclusion Criteria:

* Prior enrolment in this study
* Any prior early follicular phase serum FSH level ≥12 IU/L
* Previous poor ovarian response, defined as prior IVF cycle cancelled for poor response, or ≤4 oocytes retrieved
* IVF for pre-implantation genetic diagnosis (PGD) or fertility preservation
* Diabetes mellitus or uncontrolled thyroid disease
* Abnormal uterine cavity, such as unresected submucosal fibroids, uterine septum, Mullerian anomaly such as bicornuate or unicornuate uterus or intrauterine adhesions
* Hydrosalpinx that has not been removed or surgically ligated
* Any contraindication to endometrial biopsy
* Office hysteroscopy or other uterine procedure planned or performed during cycle preceding IVF stimulation
* Use of surgically retrieved sperm
D: Inclusion Criteria:

* Women submitted to IVF or ISCI treatment
* Age \> 18 years
* Women able to read, speak and understand Danish
* Written consent

Exclusion Criteria:

* Intrauterine abnormalities
* Infection
* BMI \> 35
* Known intrauterine cause to the infertile condition
* Abuse of alcohol or drugs
* Untreated medical condition
* Pregnancy

Answer: B